Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 15/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.69 |
| ▸ | PLK4 | O00444 | 1/20 | 0.66 |
| ▸ | CDK2 | P24941 | 1/20 | 0.66 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.66 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.66 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.66 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724510 | 0.99 | ADORA2B (0.70) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1725122 | 0.93 | ADORA2B (0.67) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL2686852 | 0.91 | ADORA2B (0.65) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL2684594 | 0.90 | ADORA2B (0.62) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1724505 | 0.90 | ADORA2B (0.64) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL2685603 | 0.90 | ADORA2B (0.63) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1723970 | 0.89 | ADORA2B (0.61) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1724676 | 0.89 | ADORA2B (0.64) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL1724675 | 0.89 | ADORA2B (0.64) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL2684651 | 0.89 | ADORA2B (0.60) | ADORA2BADORA2AADORA1ADORA3PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA2A 1/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.